Completed

Semaglutide Impact on Energy Expenditure in Weight Loss

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to measure the changes in your energy expenditure, physical activity, and resting energy expenditure while using Semaglutide for weight loss, through various methods including a 24-hour chamber, a wearable accelerometer, indirect calorimetry, and doubly labeled water analysis.

What is being tested

Semaglutide

+ Placebo

Drug
Who is being recruted

Body Weight+5

+ Nutrition Disorders

+ Nutritional and Metabolic Diseases

From 18 to 60 Years
+13 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Basic Science Study

Placebo-Controlled
Interventional
Study Start: April 2024
See protocol details

Summary

Principal SponsorShenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2024

Actual date on which the first participant was enrolled.

This study aims to explore how the medication semaglutide affects the way the body uses energy in people with obesity. Obesity is a condition where excess body fat negatively impacts health, and finding effective treatments is crucial. Semaglutide, a type of medication known as a GLP-1 receptor agonist, is known for its ability to help with weight loss by regulating hunger and controlling how the body processes sugars. This study will investigate whether semaglutide can help maintain energy expenditure levels in the body, which usually decrease with calorie restriction, thereby potentially offering a new way to aid weight loss without the typical drop in energy use. Participants in this study will receive semaglutide and their energy expenditure will be measured using specialized tools such as doubly-labelled water and respiratory chambers. These methods will help researchers understand how semaglutide influences the body's energy use compared to a standard calorie-restricted diet. The study does not specify particular risks or benefits, but it seeks to determine if semaglutide can prevent the decrease in energy expenditure that usually occurs when reducing calorie intake, which could be beneficial for managing obesity effectively.

Official TitleThe Effect of Weekly Semaglutide Treatment on Energy Expenditure
NCT06390501
Principal SponsorShenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

60 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Basic Science Study

Basic science studies help researchers understand how the body works or how a disease develops. They don't test treatments, but they build the foundation for future therapies.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionOverweight

Criteria

2 inclusion criteria required to participate
Age 18-60 years at time of enrollment
BMI ≥ 25 kg/m²
11 exclusion criteria prevent from participating
Subject with contraindication to neuroimaging by MRI
People with fear of blood and pathologically low blood pressure
Use of antibiotics and probiotics within 8 weeks
Surgical treatment for past obesity, dieting, or undergoing weight loss treatment
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Once-weekly injections of gradually increased doses of semaglutide

Group II

Placebo
Once-weekly injections of gradually increased volumes of saline placebo, to match the volumes of the semaglutide treated arm.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Shenzhen Institute of Advanced Technology

Shenzhen, ChinaOpen Shenzhen Institute of Advanced Technology in Google Maps
CompletedOne Study Center